ticlopidine has been researched along with Cholera Infantum in 22 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| " Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)." | 2.78 | Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013) |
| " Most pharmacokinetic and pharmacodynamic studies in vivo were conducted using small sample sizes and were single centered, resulting in conflicting data." | 2.49 | Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic review. ( Chen, J; Chen, SY; Lian, JJ; Luo, TC; Zeng, XQ, 2013) |
| " Until further reliable controlled data are available, this potential, but currently unproven, clinical interaction can be minimized by widely separating the dosing of clopidogrel and PPI." | 2.46 | NSAID-induced gastrointestinal and cardiovascular injury. ( Chan, FK; Ng, SC, 2010) |
| " Until further data is available, some clinical strategies can be recommended: (1) individual gastrointestinal risk assessment, with PPIs administration only to patients on dual anti-platelet therapy with additional GI risk factors; (2) preferential use of PPIs that have shown less interference with clopidogrel efficacy; (3) wide separation of PPI and clopidogrel dosing to minimize the risk of interaction (PPI may be given before breakfast and clopidogrel at bedtime); (4) or alternative use of histamine-2-receptor antagonist therapy, in patients at low GI risk." | 2.46 | [Clopidogrel--proton pump inhibitors drug interaction: implications to clinical practice]. ( Albuquerque, A; Fontes-Carvalho, R, 2010) |
| "Regardless of dose, adjusted odds ratios associating clopidogrel use with the study endpoint were statistically significant and followed a dose-response pattern." | 1.39 | Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. ( Grove, EL; Jørgensen, NR; Schwarz, P; Vestergaard, P; Würtz, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Chen, SY | 1 |
| Lian, JJ | 1 |
| Zeng, XQ | 1 |
| Luo, TC | 1 |
| Lee, T | 1 |
| Lee, R | 1 |
| Kashour, T | 1 |
| Al-Tannir, M | 1 |
| Bahamid, R | 1 |
| Lanas, A | 2 |
| Gargallo, CJ | 1 |
| Lozano, I | 1 |
| Sanchez-Insa, E | 1 |
| de Leiras, SR | 1 |
| Carrillo, P | 1 |
| Ruiz-Quevedo, V | 1 |
| Pinar, E | 1 |
| Gopar-Gopar, S | 1 |
| Bayon, J | 1 |
| Mañas, P | 1 |
| Lasa, G | 1 |
| CruzGonzalez, I | 1 |
| Hernandez, F | 1 |
| Fernandez-Portales, J | 1 |
| Fernandez-Fernandez, J | 1 |
| Pérez-Serradilla, A | 1 |
| de la Torre Hernandez, JM | 1 |
| Gomez-Jaume, A | 1 |
| Zhang, W | 1 |
| Han, Y | 1 |
| Fort, JG | 2 |
| Schofield, D | 1 |
| Tursi, JP | 1 |
| van Boxel, OS | 1 |
| van Oijen, MG | 1 |
| Hagenaars, MP | 1 |
| Smout, AJ | 1 |
| Siersema, PD | 1 |
| Ng, SC | 1 |
| Chan, FK | 1 |
| Kwok, CS | 1 |
| Nijjar, RS | 1 |
| Loke, YK | 1 |
| Fontes-Carvalho, R | 1 |
| Albuquerque, A | 1 |
| Hunfeld, NG | 1 |
| Valkhoff, VE | 1 |
| Touw, DJ | 1 |
| Sturkenboom, MC | 1 |
| Kuipers, EJ | 1 |
| Grove, EL | 1 |
| Würtz, M | 1 |
| Schwarz, P | 1 |
| Jørgensen, NR | 1 |
| Vestergaard, P | 1 |
| Tanaka, M | 1 |
| Tanaka, A | 1 |
| Suemaru, K | 1 |
| Araki, H | 1 |
| Gurbel, PA | 1 |
| Bliden, KP | 1 |
| Jeong, YH | 1 |
| Shuldiner, A | 1 |
| Chai, S | 1 |
| Gesheff, T | 1 |
| Antonino, M | 1 |
| Gesheff, M | 1 |
| Zhang, Y | 1 |
| Tantry, US | 1 |
| Hittelet, A | 1 |
| Devière, J | 1 |
| Morton, JA | 1 |
| Newton, J | 1 |
| Gray, CS | 1 |
| Vallurupalli, NG | 1 |
| Goldhaber, SZ | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Gent, M | 1 |
| Tamai, Y | 1 |
| Takami, H | 1 |
| Nakahata, R | 1 |
| Ono, F | 1 |
| Munakata, A | 1 |
| Zauner, C | 1 |
| Funk, GC | 1 |
| Birnbacher, R | 1 |
| Taniuchi, M | 1 |
| Kurz, HI | 1 |
| Lasala, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335] | Phase 1 | 30 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for ticlopidine and Cholera Infantum
| Article | Year |
|---|---|
Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic review.
Topics: Adenosine Diphosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Dru | 2013 |
Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2015 |
NSAID-induced gastrointestinal and cardiovascular injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clopidogrel; Cyc | 2010 |
Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Diseases; Human | 2011 |
[Clopidogrel--proton pump inhibitors drug interaction: implications to clinical practice].
Topics: Clopidogrel; Drug Interactions; Gastrointestinal Diseases; Humans; Platelet Aggregation Inhibitors; | 2010 |
Management of anticoagulants before and after endoscopy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Clopidogrel; Endoscopy, Gastrointestinal; G | 2003 |
Gastrointestinal complications of dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, | 2006 |
3 trials available for ticlopidine and Cholera Infantum
| Article | Year |
|---|---|
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Res | 2013 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; | 2001 |
12 other studies available for ticlopidine and Cholera Infantum
| Article | Year |
|---|---|
Ask the doctor. I need surgery for a gastrointestinal problem, and my question is how to handle my antiplatelet therapy, which I have been taking for two years since I had angioplasty. I take aspirin and clopidogrel, which were started after I had a hea
Topics: Aspirin; Clopidogrel; Contraindications; Digestive System Surgical Procedures; Dose-Response Relatio | 2012 |
Changing prescription pattern of omeprazole among patients receiving clopidogrel.
Topics: Clopidogrel; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Follow-Up Studies; Ga | 2014 |
Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol/Esomeprazole) and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2016 |
The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Topics: Adult; Aged; Aspirin; Budgets; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Female; Gast | 2017 |
[Proton pump inhibitors and clopidogrel in a patient with cardiovascular risk factors: Cardiovascular versus gastrointestinal risk?].
Topics: Algorithms; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Diseases; Humans; Platelet Aggreg | 2010 |
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Clopidogrel; Databases, Factual; Drug Interactions | 2010 |
[Clopidogrel and proton pump inhibitors: insufficient evidence of interaction].
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytoc | 2011 |
Gastrointestinal events with clopidogrel: a nationwide population-based cohort study.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Denmark; Dose-Response Relationship, Dru | 2013 |
The assessment of risk for gastrointestinal injury with anticoagulant and antiplatelet drugs: the possible beneficial effect of eicosapentaenoic Acid for the risk of gastrointestinal injury.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Eicosapentaenoic Acid; Female; Gastro | 2013 |
Counting the true cost of antiplatelet therapy for stroke prevention.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Cost-Benefit Analysis; Dipyridam | 2005 |
Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus.
Topics: Adult; Aspirin; Bleeding Time; Cilostazol; Fibrinolytic Agents; Gastrointestinal Diseases; Headache; | 1999 |
Platelet aggregation inhibition with ticlopidine in the treatment of stroke.
Topics: Acute Disease; Critical Care; Drug Eruptions; Drug Monitoring; Gastrointestinal Diseases; Humans; Ki | 2001 |